TY - JOUR
T1 - The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies
AU - Haase, Michael
AU - Devarajan, Prasad V
AU - Haase-Fielitz, Anja
AU - Bellomo, Rinaldo
AU - Cruz, Dinna N
AU - Wagener, Gebhard
AU - Krawczeski, Catherine Dent
AU - Koyner, Jay L
AU - Murray, Patrick
AU - Zappitelli, Michael
AU - Goldstein, Stuart L
AU - Makris, Konstantinos
AU - Ronco, Claudio
AU - Martensson, Johannes Karl
AU - Martling, Claes-Roland
AU - Venge, Per
AU - Siew, Edward
AU - Ware, Lorraine B
AU - Ikizler, Talat Alp
AU - Mertens, Peter Rene
PY - 2011
Y1 - 2011
N2 - The aim of this study was to test the hypothesis that, without diagnostic changes in serum creatinine, increased neutrophil gelatinase-associated lipocalin (NGAL) levels identify patients with subclinical acute kidney injury (AKI) and therefore worse prognosis. Background: Neutrophil gelatinase-associated lipocalin detects subclinical AKI hours to days before increases in serum creatinine indicate manifest loss of renal function. Methods: We analyzed pooled data from 2,322 critically ill patients with predominantly cardiorenal syndrome from 10 prospective observational studies of NGAL. We used the terms NGAL(-) or NGAL(+) according to study-specific NGAL cutoff for optimal AKI prediction and the terms sCREA(-) or sCREA(+) according to consensus diagnostic increases in serum creatinine defining AKI. A priori-defined outcomes included need for renal replacement therapy (primary endpoint), hospital mortality, their combination, and duration of stay in intensive care and in-hospital.
AB - The aim of this study was to test the hypothesis that, without diagnostic changes in serum creatinine, increased neutrophil gelatinase-associated lipocalin (NGAL) levels identify patients with subclinical acute kidney injury (AKI) and therefore worse prognosis. Background: Neutrophil gelatinase-associated lipocalin detects subclinical AKI hours to days before increases in serum creatinine indicate manifest loss of renal function. Methods: We analyzed pooled data from 2,322 critically ill patients with predominantly cardiorenal syndrome from 10 prospective observational studies of NGAL. We used the terms NGAL(-) or NGAL(+) according to study-specific NGAL cutoff for optimal AKI prediction and the terms sCREA(-) or sCREA(+) according to consensus diagnostic increases in serum creatinine defining AKI. A priori-defined outcomes included need for renal replacement therapy (primary endpoint), hospital mortality, their combination, and duration of stay in intensive care and in-hospital.
UR - http://www.sciencedirect.com/science/article/pii/S0735109711005754
U2 - 10.1016/j.jacc.2010.11.051
DO - 10.1016/j.jacc.2010.11.051
M3 - Article
SN - 0735-1097
VL - 57
SP - 1752
EP - 1761
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 17
ER -